CAR-T Cells and the Kidney: Insights from the WHO Safety Database.

Alexandre Olivier Gérard Diane MerinoAlexis CharbinatJoseph FournierAlexandre DestereMichael Loschi Thomas Cluzeau Antoine Sicard Milou-Daniel Drici

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)

This study is limited by the inherent flaws of pharmacovigilance approaches. Nonetheless, our findings suggest that ARF and an array of hydroelectrolytic disorders are potential ADRs of CAR-T cell therapy, in real-life settings and in a nonselected population.

Keyphrases

cell therapy
induced apoptosis
adverse drug
stem cells
mesenchymal stem cells
cell cycle arrest
emergency department
high resolution
high throughput
bone marrow
signaling pathway
oxidative stress
mass spectrometry
drug induced